Mixed Results for Immunotherapy in Metastatic Prostate Cance

Mixed Results for Immunotherapy in Metastatic Prostate Cancer


email article
An immunotherapy combination for metastatic castration-resistant prostate cancer (mCRPC) failed to hit a response target but still exceeded historical results, a small prospective study showed.
Ten of 35 (28.6%) patients responded to the combination of nivolumab (Opdivo) and ipilimumab (Yervoy). The activity fell short of the 40% threshold for a positive outcome but well above the historical response rate for immunotherapy in patients previously treated with docetaxel.
The safety profile of the combination was consistent with prior clinical experience, reported Mark Linch, MD, PhD, of University College London, at the American Association for Cancer Research virtual meeting.
"Responders were enriched with patients with mismatch repair or BRCA 1 and 2," said Linch. "We believe that further study of nivolumab and ipilimumab i biomarker-selected patients with metastatic castration-resistant prostate cancer is warranted. The rate of incomplete treatment was high, suggesting that alternate dosing schedules may be required."

Related Keywords

United States , American , Charles Bankhead , University College London , American Association For Cancer Research , Mark Linch , American Association , Cancer Research , Medpage Today , Carcinoma Of Prostate , Malignant Tumor Of Prostate , Secondary Malignant Neoplastic Disease , ஒன்றுபட்டது மாநிலங்களில் , அமெரிக்கன் , சார்லஸ் வங்கித் தலை , பல்கலைக்கழகம் கல்லூரி லண்டன் , அமெரிக்கன் சங்கம் க்கு புற்றுநோய் ஆராய்ச்சி , அமெரிக்கன் சங்கம் , புற்றுநோய் ஆராய்ச்சி , புற்றுநோய் ஆஃப் ப்ராஸ்டேட் , வீரியம் மிக்கது கட்டி ஆஃப் ப்ராஸ்டேட் ,

© 2025 Vimarsana